William Park, MD
Pulmonary Disease · Renton, WANPI 1205949195
Payments from drug & device makers
What this record shows
This record is dominated by grants: $5,000 of the $5,246 with a category attached, or 95.3%. Boston Scientific accounts for 95.3% of it on its own, with 1 other manufacturer making up the rest.
Across 2 payments — averaging $2623.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Inari Medical, Inc.$246
Across 64 payments — averaging $18,451 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$723K
- Merck$437K
- AstraZeneca$11K
- Chiesi USA, Inc.$9K
What the payments were for
- Grants$5,00095%
- Food & beverage$2465%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 1 | $5,000 |
| Inari Medical, Inc. | 1 | $246 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,246 in reported general payments places this provider in the 80th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $326,471 |
| Dupixent SyringeDupilumab | 44 | $166,650 |
| Spiriva RespimatTiotropium Bromide | 161 | $122,730 |
| Dupixent PenDupilumab | 28 | $104,866 |
| Pirfenidone | 21 | $100,986 |
| TezspireTezepelumab-Ekko | 22 | $95,661 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $77,340 |
| NucalaMepolizumab | 17 | $72,791 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 94 | $50,816 |
| Breo ElliptaFluticasone/Vilanterol | 92 | $47,585 |
| SymbicortBudesonide/Formoterol Fumarate | 76 | $28,752 |
| EliquisApixaban | 15 | $20,609 |
| Arnuity ElliptaFluticasone Furoate | 57 | $20,023 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $15,771 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 134 | $13,377 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Renton
- Richard KimRenton$9K
- Hina SahiRenton$4K
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Jiten PatelSpokane$200K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Nicholas WyshamVancouver$117K
- Colleen OverdorfBellingham$110K
- Jeffrey CarySeattle$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.